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A B S T R A C T
Malaria is one of the world’s most common and serious diseases causing death of about 3 million people
each year. Its most severe occurrence is caused by the protozoan Plasmodium falciparum. Biomedical
research could enable treating the disease by effectively and specifically targeting essential enzymes of
this parasite. However, the parasite has developed resistance to existing drugsmaking it indispensable to
discover new drugs. We have established a simple computational tool which analyses the topology of the
metabolic network of P. falciparum to identify essential enzymes as possible drug targets.We investigated
the essentiality of a reaction in themetabolic network by deleting (knocking-out) such a reaction in silico.
The algorithm selected neighbouring compounds of the investigated reaction that had to be produced by
alternative biochemical pathways. Using breadth first searches, we tested qualitatively if these products
could be generated by reactions that serve as potential deviations of the metabolic flux. With this we
identified 70 essential reactions. Our results were compared with a comprehensive list of 38 targets of
approved malaria drugs. When combining our approach with an in silico analysis performed recently
[Yeh, I., Hanekamp, T., Tsoka, S., Karp, P.D., Altman, R.B., 2004. Computational analysis of Plasmodium
falciparum metabolism: organizing genomic information to facilitate drug discovery. Genome Res. 14,
917–924] we could improve the precision of the prediction results. Finally we present a refined list of 22
new potential candidate targets for P. falciparum, half of which have reasonable evidence to be valid
targets against micro-organisms and cancer.
 2008 Elsevier B.V. All rights reserved.
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Malaria kills about 3 million people each year, of which more
than 1 million are children under the age of five. In addition, up to
half a billion people suffer from the effects of malaria (Snow et al.,
2001). Although there are several different treatments for malaria,
the parasite is becoming increasingly resistant to conventional
antimalarial drugs. This has contributed to increasing morbidity
and mortality. Four species of the Plasmodium genus cause human
malaria. Among these, Plasmodium falciparum inflicts the most
mortality and is responsible for about 90% of malaria deaths.* Corresponding author at: Bioinformatics and Functional Genomics, Institute of
Pharmacy and Molecular Biotechnology, University of Heidelberg, Germany.
Tel.: +49 6221 5451290; fax: +49 6221 5451488.
E-mail addresses: r.eils@dkfz.de (R. Eils), r.koenig@dkfz.de (R. Ko¨nig).
1567-1348/$ – see front matter  2008 Elsevier B.V. All rights reserved.
doi:10.1016/j.meegid.2008.01.007Besides this, in biomedical research a considerable amount of data
has been generated. Functional genomics of P. falciparum has been
studied observed by the completion of sequencing the genome
(Gardner et al., 2002), a variety of gene expression studies (e.g.
Bozdech et al., 2003) and the setting up of a comprehensive
metabolic reaction database (Yeh et al., 2004). Methodologically,
such a reaction database can be used to construct and system-
atically analyse a metabolic network by linking pairs of reactions
for which the product of one reaction is the substrate for the other.
Such metabolic networks have been analysed with graph-based
algorithms to identify drug targets in pathogenic organisms. For
example, the term ‘‘damage’’ was defined to assess the enzymes
that may serve as drug targets when their inhibition influences a
broader amount of downstream reactions and products (Lemke
et al., 2004; Mombach et al., 2006). Flux balance analysis (FBA) is a
widely used andwell-establishedmethod to assess the essentiality
of genes for an organism (Becker et al., 2007; Edwards and Palsson,
Fig. 1. The knocked out reaction is a choke-point but may not be essential for the
organism if the dashed lines exist in the metabolic network. Our approach inspects
the network for such deviations (see text). Reactions are illustrated as boxes,
metabolites as circles.
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integrated metabolic networks using dynamic mass balance
equations. The concentration change of a metabolite over time
is equal to the difference between the rates at which the
metabolite is produced and consumed. In a steady state, the net
concentration change of an inner metabolite in the network can
then be modelled to be zero analogous to Kirchhoff’s first law for
electrical circuits (Edwards et al., 2002). However, FBA approaches
need clear specifications defining nutrition availability and
biomass production under specifically given environmental
conditions (for a good overview of these aspects see (Schuetz
et al., 2007)). Furthermore, concepts of choke-points and load-
points were used to estimate if reactions are essential for the
organism (Rahman and Schomburg, 2006; Yeh et al., 2004). In an
extended graph theory model load-points were defined as nodes
with a large number of k-shortest paths passing through them,
which indicates high impact on metabolism. Load-points are
defined as hot spots in the metabolic network (enzymes/
metabolites) based on the ratio of the number of k-shortest paths
passing through a metabolite/enzyme (in/out), and the number of
nearest neighbour links (in/out) attached to it. This ratio is
compared to the average load value in the network (Rahman and
Schomburg, 2006). Choke-points uniquely consume or produce a
certain metabolite, which may make them indispensable. It could
be shown that inactivating choke-points leads to an organism’s
failure. For example, in P. falciparum d-aminolevulinate dehydra-
tase (ALAD) has been considered as a choke-point (Yeh et al., 2004).
In fact, d-aminolevulinate dehydratase is involved in heme
biosynthesis and can serve as a valid antimalarial target (Bonday
et al., 2000). With a choke-point analysis, Yeh et al. (2004)
identified 216 enzymatic activities as catalysing choke-point
reactions, assuming each enzyme has only one active site, unless
annotated as multifunctional. If an enzyme catalysed at least one
choke-point reaction, it was classified as a potential drug target.
Within the 216 identified potential targets, they identified three
targets of clinically proven drugs and 24 proposed drug targets
with biological evidence (such as in vitro growth inhibition of the
parasite with target inhibition). However, the precision (number of
true predictions out of all predictions) of their approach is limited
which makes it difficult for an experimentalist to choose the
appropriate potential drug target when developing inhibitors as
effective therapeutics.
In our work we used the data of the metabolic reaction
database PlasmoCyc (Yeh et al., 2004) and developed an algorithm
that analyses the topology of the metabolic network for P.
falciparum. Basically, each reaction in the network was deleted
(knocked out in silico), respectively. A breadth first search
algorithm tested if the neighbouring compounds of the knocked
out reaction could be produced by other reactions and pathways
of reactions. In contrast to the choke-point approach, we checked
the principle that deviations in the network could be used to
replace the knocked out reaction. Fig. 1 illustrates this. The
knocked out reaction is a choke-point, as metabolite D is uniquely
produced by this reaction. However, Dmay not be essential for the
organism if E and F can be produced using A and B as substrates for
reactions r4 and r2, respectively (dashed lines in Fig. 1). To
estimate the performance of our method, we defined a gold
standard. For this, we assembled publically available data of
approved and experimentally validated drugs for P. falciparum
and yielded a list of 38 reactions within our network that are
successfully targetable. Note that, this is not a true gold standard
in the sense that a lot of true positves may have not been
discovered yet. We used the gold standard for estimating the
prediction performance of our algorithm, in comparison to the
choke-point approachpredicting andoptimising anenrichment ofdiscovered drug targets (enrichment of reactions from the gold
standard). In addition, one can assume that enriching discovered
drug targets comprises an enrichment of non-discovered drug
targets, which then can be found in the list of false positive
predictions.
In comparison to the choke-point analysis (Yeh et al., 2004), we
were able to improve the prediction results when combining our
method with the choke-point method. Using the choke-point
analysis alone yielded an accuracy of 68% and a precision of 19%,
whereas, applying the choke-point analysis together with our
method, yielded an increased accuracy of 88% and a precision of
29%. Finally, we analysed the ‘‘false’’ positives. This list may serve
as candidates for new drug targets. We tested the sequences of
these candidates for sequence homology to the human genome to
exclude severe physiological side effects when targeting. Finally,
an assembled list of 22 potential new drug targets is presented.
Eleven of which are reported in the literature as drug targets
against micro-organisms and cancer.
2. Materials and methods
2.1. Reconstructing the metabolic network
All metabolic reactions were extracted from the PlasmoCyc
database ((Karp et al., 2005), http://www.biocyc.org, Version 10.5).
As described elsewhere (Ko¨nig and Eils, 2004) a connected graph
was established by defining neighbours of reactions: two reactions
were neighbours if a metabolite existed that was the product of
one reaction and the substrate for the other. This yielded a bipartite
graph of alternating reaction and metabolic compound nodes.
Metabolites that were highly connected and therefore pathway
unspecific, such as water, oxygen and ATP were discarded. This
yielded a network with 554 metabolites and 575 reactions. As
there was no information available, each reaction was considered
to be reversible.
2.2. The algorithm
Basically, the producibility of a network having a deleted
reaction (‘‘mutated network’’ in the following) was compared to
the wild-type network without the deletion. These comparisons
were performed for each reaction. A reaction was given out as
essential if producing products downstream of it was indicated to
hamper. In detail, the procedure was as follows:
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(2) A set of products S was assembled containing all metabolites
that were produced downstream from the deleted reaction. To
gain a higher variability, we added also all metabolites of the
products of all reactions that had theses metabolites as
substrates.(3) From this set, we sampled 1000 smaller subsets si, i = 1, . . .,
1000, containing randomly drawn metabolites from S. si had
got a size of 30% of S.(4) i was set to 1.
(5) The mutated network was tested if it was able to produce all
elements of si using all reactions and metabolites of the
network. To avoid trivial solutions, metabolites that were
contained in si could not serve as substrates. If producing the
subset si was possible, pm was set to one, otherwise to zero.
Furthermore, the mutated network was tested for its effec-
tiveness. For this, a minimum number of necessary reactions
and metabolites were assessed by a greedy approach: a list of
all reactions (except the knocked out reaction) was composed
by sampling without replacement. Starting from the top (and
ending at the bottom) of the list, each reaction was tested if it
could be discardedwithout losing the possibility to produce the
elements of si. This test was performed by a common breadth
first search on graphs (see, e.g. Cormen et al., 1995). Every time
this test failed, the respective reaction was placed back into the
network and the next one in the list was tested. The resulting
number of reactions was rm. The same was performed with a
list of all metabolites of the network yielding an estimated
minimal set of necessary metabolites mm.(6) The same tests (using the same lists of reactions and
metabolites) were performed with the wild-type network
yielding pw (equaling one if producing all products of si,
otherwise zero) and the assessed minimal number of reactions
rw and metabolites mw.(7) Steps (5) and (6) were repeated for every i = 1 to 1000. Mean
values for the variables pm, pw, mm, mw, rm, rw were calculated
yielding hpmi, hpwi, hmmi, hmwi, hrmi, hrwi. A reaction was
estimated to be essential if
hpmi < hpwi and (hrmi > hrwi or hmmi > hmwi).
Additionally, reactions with connectivity higher than 10
were discarded to restrict the predictions to non-hub like
reactions.(8) Steps (2)–(7)were performed for every reaction in the network.
2.3. The gold standard and statistical settings
We assembled a list of proposed drug targets from the
literature. We used the list of Yeh et al. (2004) comprising of
three targets of clinically proven drugs and 24 proposed drug
targets with biological evidence, such as in vitro growth inhibition
of P. falciparum (for details, see Yeh et al., 2004). Additionally, we
found further drug targets when scanning a variety of established
databases, i.e. Drugbank (www.redpoll.pharmacy.ualberta.ca/
drugbank), TDR Target Database (www.tdrtarget.org) and the
database for Malaria Parasite Metabolic Pathways by Hagai
Ginsburg (http://www.sites.huji.ac.il/malaria/, see also (Ginsburg,
2006)). To equally compare all predictions with the gold standard,
every reaction of the network was mapped to its corresponding
enzyme classification (EC) number. For performance estimations,
reactions without an EC numberwere not taken into account.With
this, our network contained 38 reactions from the gold standard
and consisted of a total of 411 reactions. The complete list of the
gold standard is given in Table 1. To yield a valid comparison of the
algorithmswe did not take the reactions into account thatwere not
in the network. As our network was constructed as a connectedgraph, we discarded all reactions that were not joined with the
bulk of the graph. With this construction the following reactions
which have been shown to serve as valid drug targets where not
included in the network: enoyl-[acyl-carrier protein] reductase
(NADH) (EC 1.3.1.9) (Surolia and Surolia, 2001), DNA-directed DNA
polymerase (EC 2.7.7.7) (Barker et al., 1996), thioredoxin reductase
(NADPH) (EC 1.8.1.9) (Krnajski et al., 2002), lysophospholipase (EC
3.1.1.5) (Zidovetzki et al., 1994) and DNA-directed RNA polymer-
ase (EC 2.7.7.6) (Lin et al., 2002).
3. Results
Three different scenarios were compared, (i) the choke-point
analysis as described recently (the choke-point list was taken from
Yeh et al., 2004, for details see there), (ii) ourmethodalone, and (iii) a
combination of both where a reaction was assessed as essential if it
was a choke-point and essential according to our method. We
evaluated the performance of all three approaches with the gold
standard consisting of reactions that are targets of approved and
tested drugs. The results are given in Tables 2–4, respectively. Note
that the tables represent confusionmatrices showing true positives,
false positives, false negatives and true negatives, from left to right
and top to bottom, respectively. Using the choke-point approach
alone yielded an accuracy of 68% (accuracy = all correct predictions
divided by all predictions 100%). With our approach alone, we
yielded an accuracy of 80%. The best accuracy of 88% was achieved
when taking the intersection of essential reactions from the choke-
point analysis and ourmethod.Wewere especially interested in the
precision (true positives of all positive predictions) to serve
experimentalists with a reduced number of wrong estimates and
therefore giving them a reduced load of non-profitable assignments.
Also here the results were best when combining both approaches
(combined: 29%, choke-point alone: 19%, our method alone: 17%).
Note that the combined approach yielded a rather low sensitivity
(23%). A high sensitivity could be reached by assembling the union of
both algorithms (sensitivity = 82%, accuracy = 60%, precision = 16%).
The complete list for the union is given in the supplement
(supplementary Table S1). The parameter sp for step 3 in the
algorithm was set to its value of sp = 30% after initial trials with
sp = 20%, 30% and 40%. With sp = 20% we got lower accuracy and
precision by 1% and 4%, respectively. Choosing sp = 40% yielded
slightly better values (accuracy: +1%, precision: +2%) compared to
sp = 30%. However, with sp = 40% we could not get the products
(pw = 0) even for the wild-type for subsets si in more than 990 out of
1000 runs for 8%of all tested reactions (compared to0.3% for sp = 30%
and sp = 20%), making the comparison between wild-type and
mutant for these reactions less reliable. This behaviour is due to a
blocking effect as each selected substrate of si cannot be used as an
intermediate to obtain the products from the other substrates. The
list of the gold standard may not be complete and rather lack of
putative new drug targets. Therefore, we took all enzymes of the
positive predictions from our combined analysis as putative novel
drug targets. From these enzymes, all corresponding genes were
compared to all transcripts of the human genome using BLAST
(Altschul et al., 1997) and the ENSEMBL database (Hubbard et al.,
2007). Arginine-tRNA ligase showed some homology with E-value
4 104 andmay needmore detailedhomology investigations of its
active domain. For the rest, we did not find any significant
homologies (all E-values> 0.01). Table 5 shows the resulting list
with the best hits and their respective E-values.
3.1. Comparing our predicted drug targets with the literature
We searched through the literature in-depth to compare our
results (Table 5) with treatments and findings for other micro-
Table 1
The gold standard.
EC Reaction Found by
our method
Choke-points Found by a
combination
Reference
1.1.1.205 IMP dehydrogenase No No No Webster and Whaun (1982)
1.17.4.1 Ribonucleoside-diphosphate reductase No Yes No Chakrabarti et al. (1993)
1.2.4.4 3-Methyl-2-oxobutanoate dehydrogenase (lipoamide) Yes Yes Yes Lau et al. (1990)
1.3.3.1 Dihydroorotate oxidase No No No Baldwin et al. (2005), Boa et al. (2005),
Heikkila et al. (2006), McRobert and
McConkey (2002)
1.3.99.1 Succinate dehydrogenase No No No Suraveratum et al. (2000)
1.5.1.3 Dihydrofolate reductase No Yes No Le Bras and Durand (2003)
1.6.5.3 NADH dehydrogenase (ubiquinone) No Yes No Krungkrai et al. (2002)
2.1.1.100 Protein-S-isoprenylcysteine-O-methyltransferase No No No Baron et al. (2007),
Winter-Vann et al. (2005)
2.1.1.45 Thymidylate synthase No Yes No Jiang et al. (2000)
2.1.1.64 3-Demethylubiquinone-9,3-O-methyltransferase No Yes No Massimine et al. (2006)
2.3.1.15 Glycerol-3-phosphate-O-acyltransferase No Yes No Ginsburg (2006)
2.3.1.41 3-Oxoacyl-[acyl-carrier protein] synthase No Yes No Waller et al. (2003)
2.4.2.1 Purine-nucleoside phosphorylase No Yes No Kicska et al. (2002)
2.4.2.8 Hypoxanthine phosphoribosyltransferase No No No Sarma et al. (1998)
2.5.1.15 Dihydropteroate synthase No Yes No Triglia et al. (1997)
2.5.1.16 Spermidine synthase Yes Yes Yes Haider et al. (2005)
2.5.1.18 Glutathione transferase Yes No No Fritz-Wolf et al. (2003),
Harwaldt et al. (2002),
Liebau et al. (2002),
Perbandt et al. (2004)
2.5.1.19 3-Phosphoshikimate 1-carboxyvinyltransferase Yes Yes Yes Roberts et al. (1998)
2.5.1.21 Farnesyl-diphosphate farnesyltransferase Yes Yes Yes Chakrabarti et al. (2002)
2.7.1.32 Choline kinase Yes No No Ancelin and Vial (1986)
3.1.3.56 Inositol-1,4,5-trisphosphate 5-phosphatase Yes Yes Yes Ogwan’g et al. (1993)
3.1.4.12 Sphingomyelin phosphodiesterase No Yes No Hanada et al. (2002)
3.1.4.17 30 ,50-Cyclic-nucleotide phosphodiesterase Yes Yes Yes Yuasa et al. (2005)
3.3.1.1 S-adenosyl-L-homocysteine hydrolase No Yes No Kitade et al. (1999), Shuto et al. (2002)
3.5.4.4 Adenosine deaminase No No No Tyler et al. (2007)
3.6.1.17 Bis(50-nucleosyl)-tetraphosphatase (asymmetrical) No Yes No Guranowski et al. (2003)
4.1.1.17 Ornithine decarboxylase No Yes No Berger (2000)
4.1.1.23 Orotidine-50-phosphate decarboxylase Yes No No Krungkrai et al. (2005),
Scott et al. (1986),
Seymour et al. (1994)
4.1.1.50 Adenosylmethionine decarboxylase No Yes No Wright et al. (1991)
4.1.2.13 Fructose-bisphosphate aldolase No Yes No Wanidworanun et al. (1999)
4.2.1.24 Delta-aminolevulinic acid dehydratase No Yes No Bonday et al. (2000)
4.2.3.5 Chorismate synthase No Yes No McRobert and McConkey (2002)
4.4.1.5 Lactoylglutathione lyase Yes Yes Yes Thornalley et al. (1994)
6.1.1.3 Threonine-tRNA ligase Yes Yes Yes Ruan et al. (2005)
6.1.1.7 Alanine-tRNA ligase No Yes No Corvaisier et al. (2003)
6.3.2.2 Gamma-glutamylcysteine synthetase Yes Yes Yes Meierjohann et al. (2002)
6.3.5.5 Carbamoyl-phosphate synthase (glutamine-hydrolysing) No Yes No Flores et al. (1997)
6.4.1.2 Acetyl-CoA carboxylase No No No Waller et al. (2003)
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found that it has already been described to be a drug target in P.
falciparum (marked by ****, Table 5 and see below), for four we
found clear evidence to be targeted against other microbial
diseases (***), for two we found anticancer drugs (**) and for four
we found reasonable evidence to be targeted against other
diseases (*). Furthermore, we compiled some interesting infor-
mation for four enzymes which may not serve as drug targets (noTable 2
Results using the choke point approach alone (accuracy: 68%, precision: 19%).
Truth (state of the art)
Known drug target
(‘‘essential’’)
Not known as a
drug target
(‘‘non-essential’’)
Sum
Prediction
Essential 28 123 151
Non-essential 10 250 260
Sum 38 373 411asterisks). In the following, our findings are described in more
detail.
***EC 2.1.2.9: Inhibiting methionyl-tRNA formyltransferase
caused impaired growth in Escherichia coli (Mazel et al., 1994).
EC 2.4.2.11: Nicotinate phosphoribosyltransferase reduces
oxidative stress (Hara et al., 2007). Zerez et al. (1990) observed
a threefold increase of Nicotinate phosphoribosyltransferaseTable 3
Results using our method alone (accuracy: 80%, precision: 17%).
Truth (state of the art)
Known drug target
(‘‘essential’’)
Not known as a
drug target
(‘‘non-essential’’)
Sum
Prediction
Essential 12 58 70
Non-essential 26 315 341
Sum 38 373 411
Table 4
Results assessing a reaction essential if it is a choke point and essential according to
our method (accuracy: 88%, precision: 29%).
Truth (state of the art)
Known drug
target (‘‘essential’’)
Not known as a
drug target
(‘‘non-essential’’)
Sum
Prediction
Essential 9 22 31
Non-essential 29 351 380
Sum 38 373 411
Tab
Pre
EC
2.1.
2.4.
2.4.
2.4.
2.5.
2.5.
2.7.
2.7.
2.7.
2.7.
2.7.
2.7.
2.7.
2.7.
3.1.
3.5.
4.1.
4.2.
4.2.
4.2.
6.1.
6.2.
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target specifically as the human red blood cell produces this
enzyme.
**EC 2.4.2.30: NAD(+) ADP-ribosyltransferase is a well known
anticancer drug (Ratnam and Low, 2007).
****EC 2.5.1.46: Deoxyhypusine synthase is a knowndrug target
for P. falciparum (Moritz et al., 2004).
*EC 2.7.1.1: Hexokinase activity in cell-free Plasmodium berghei
was observed to be 35 and 5 times higher as compared to
normal and P. berghei-infected mouse erythrocytes, respec-
tively (Kumar and Banyal, 1997). Therefore, blocking of
hexokinase may yield synergistic effects when combining it
with blocking hemoglobin ingestion and degradation as the
major nutrient uptake channel.
*EC2.7.1.35: Besides vitaminB6 (Ebadi et al., 1982), aminphylline
also isblockingtheenzymepyridoxal kinase (Delport etal., 1990).
In turn, aminophylline is aiding antibiotics to prevent resistance
in S. aureus and P. aeruginosa (Hosseinzadeh et al., 2006).
Enzymes EC 2.7.1.50 and EC 2.7.4.7 are involved in the
biosynthesis of the vitamin thiamine. Blocking these enzymes
may stop the biosynthesis of thiamine. However, thiamine may
not be essential for the parasite in rich media.
*EC 2.7.4.9 (thymidylate kinase/DTMP kinase): We could not
find a drug targeting thymidylate kinase. Thymidylate kinase is
one step in the biosynthesis pathway of deoxythymidine
triphosphate (dTTP). dTTP is needed for, e.g. synthesising DNA.
Nevertheless, is has been shown very recently that the direct
upstream reaction, thymidine kinase, has been successfullyle 5
dicted potential drug targets.
Reaction
2.9 Methionyl-tRNA formyltransferase
1.119 Dolichyl-diphosphooligosaccharide–protein glycosyltransferase
2.11 Nicotinate phosphoribosyltransferase
2.30 NAD(+) ADP-ribosyltransferase
1. Glutamyl-tRNA(Gln) amidotransferase
1.46 Deoxyhypusine synthase
1.1 Hexokinase
1.35 Pyridoxal kinase
1.50 Hydroxyethylthiazole kinase
4.7 Phosphomethylpyrimidine kinase
4.9 Thymidylate kinase
7.2 FMN adenylyltransferase
8.- Cardiolipin synthetase
8.11 CDP-diacylglycerol–inositol 3-phosphatidyltransferase
2.6 Hydroxyacylglutathione hydrolase
1.19 Nicotinamidase
2.4 Deoxyribose-phosphate aldolase
1.17 Enoyl-CoA hydratase
1.60 3-Hydroxydecanoyl-[acyl-carrier protein] dehydratase
1.70 Pseudouridylate synthase
1.19 Arginine-tRNA ligase
1.3 Long-chain-fatty-acid-CoA ligasetargeted for inhibiting growth of Mycobacterium tuberculosis
(Van Daele et al., 2007). We therefore suggest thymidylate
kinase as a good potential drug target with similar effects.
***EC 2.7.8.11: It has been shown that phosphatidylinositol
synthase is essential in Trypanosoma brucei (Martin and Smith,
2006).
***EC 3.1.2.6: Hydroxyacyl glutathione hydrolase has been
suggested as an antimicrobial drug against Leishmania (Pad-
manabhan et al., 2006).
EC 3.5.1.19: Nicotinamidase is used in M. tuberculosis to
metabolite pyrazinamide into pyrazionic acid which in turn
gives the antibacterial effect of the treatment. Hence, in this
case treating a patient by blocking nicotinamidase yields an
antagonistic response when administering pyrazinamide at the
same time (Scorpio and Zhang, 1996). However, we could not
find any literature describing the effects when exclusively
inhibiting nicotinamidase.
***EC 4.2.1.60: 3-Hydroxydecanoyl-ACP dehydrase is essential
inM. tuberculosis and serves as a good candidate for drug targets
(Sacco et al., 2007).
**EC 6.1.1.19: Arginine-tRNA ligase serves as a potential drug
target against cancer of the pancreas (Bence and Crooks, 2003).
*EC 6.2.1.3: It is assumed that long-chain-fatty-acid CoA ligase
is inhibited by a rice herbicide preventing the biosynthesis of
very-long-chain fatty acids (Takahashi et al., 2001). Note that
this reaction may be used in Plasmodium within the fatty acid
beta-oxidation II pathway which is normally found in plants.
4. Discussion
We have established a simple method that analyses metabolic
pathways and identifies essential reactions as potential drug
targets in the metabolic network of P. falciparum. Using the target
reactions of approved drugs as a gold standard, we yielded more
precise predictions when combining our method with the
established approach of choke-point analysis. This makes sense,
as additional to the choke-point analysis we carefully checked for
alternative pathways that may generate the products of the tested
knock-out reactions. In turn, ourmethod alone also yielded a lower
precision and accuracy compared to the combined approach. This
may be due to the fact that our algorithm simply searches for anyEvidence Genes Human homologs E-value
*** MAL13P1.67 ENST00000373665 0.19
PFI0960W ENST00000306726 0.034
MAL6P1.137 ENST00000370856 0.19
** PFI1005W ENST00000282892 0.052
MAL6P1.78 ENST00000340159 0.009
**** PF14_0125 ENST00000352853 0.54
* MAL6P1.189 ENST00000240487 0.14
* MAL6P1.266 ENST00000234179 0.011
PFL1920C ENST00000346134 0.005
PFE1030C ENST00000382103 0.086
* PFL2465C ENST00000340245 0.90
PF10_0147 ENST00000256103 0.091
MAL6P1.97 ENST00000233710 0.66
*** MAL13P1.82 ENST00000321998 0.19
*** PFL0285W ENST00000389580 0.35
PFC0910W ENST00000294671 0.12
PF10_0210 ENST00000356689 0.29
PF10_0167 ENST00000335407 0.16
*** PF13_0128 ENST00000297933 0.25
PFB0890C ENST00000370920 0.37
** PFL0900C ENST00000231572 2e-04
* PF14_0761 ENST0000038037 0.23
PFB0695C ENST00000373480 0.063
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always serve as a valid replacement. This is especially the case,
when analysing higher connected reactions. After testing a variety
of different upper boundary values, we restricted the connectivity
of predicted essential reactions to an optimal upper limit of 10.
However, drugable reactions with higher connectivity could
therefore not be discovered: The mean connectivity of our true
positive predictions was 2.6. In contrast, essential reactions that
we could not discover (false negatives) had an increased mean
connectivity of 6.5. For the choke-point approach both values were
comparable (mean connectivity was 5.1 for true positives and 5.4
for false negatives). This emphasizes to apply the combination of
both approaches: assembling the union of the predictions from
both methods yielded a good sensitivity (82%) whereas their
intersection yielded an improved precision (29%) and a good
accuracy of 88%. However, the precision of 29% was also not very
high. The reason for this is twofold: we need to improve our
algorithm and some of our false positive predictions are indeed
valid new drug targets. With at least a reasonable evidence, this
could be experimentally shown for half of these targets (11 out of
22, see Section 3). In addition, if regarding the KEIO knock-out
collection for E. coli, in which every open reading frame was
knocked out and tested for its essentiality, around 300 ORFs were
observed to be essential (Baba et al., 2006). Wemapped these ORFs
to their according reactions and found around 100 metabolic
reactions to be essential in E. coli. Transferring this order of
magnitude to our case, we estimate that until now only about half
of all essential reactions in P. falciparum may have been
experimentally validated and targeted so far. In comparison to
the choke-point analysis, we yielded a rather low sensitivity (our
method: 32%, choke-point: 74%, combined: 24%). However, it was
not our aim to predict a large list of potential targets with a high
number of false positives. We calculated a smaller defined list of
concrete candidate targets to be tested in the lab. For our concept,
no initial settings are needed. This makes its application easier in
comparison to flux balance analyses, where the environmental
conditions need to be defined, such as availability of nutrients, the
carbon sources and temperature. In contrast, we restricted our
method to scan over the local topological properties of the
network, around the investigated reaction. Such a concept may be
combined with a flux balance analysis by defining the investigated
region of the network and restricting to local subnets, making FBA
more independent from environmental settings. Furthermore,
concepts like estimating the damage (Lemke et al., 2004) may be
further included in such approaches by taking the substantially
effected downstream regions of the metabolism into account.
Knocking-out open reading frames has been performed in high
throughput for several organisms including E. coli (Baba et al.,
2006), yeast (Giaever et al., 2002) and Candida albicans (Roemer
et al., 2003). Even though such studies are costly and labour
intensive it is quite likely that they will also be performed with
Plasmodium in the near future. It will be interesting to compare our
in silico predictions with such experimental data. But note that in
contrast to these experimental approaches, our in silico predictions
are feasible to also handle multiple knock-outs on a high
throughput yielding possible effective drug combinations. We
plan to do this when some data of at least a limited amount of drug
combinations has been made available. In conclusion, our
approach is computational inexpensive and simple to implement,
it limits time and cost consuming wet lab experiments and has got
the potential to serve as a valid technique to be combined with
other established graph-based investigations of themetabolism. In
principle, such in silico investigations can be performed for any
organism if its genome and its inferred metabolic network is
discovered sufficiently enough.Acknowledgements
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